Target intelligence / Profile preview

Neisserial heparin binding antigen, Neisserial adhesin A, factor H binding protein, and PorA (Combined Meningococcal Vaccine Antigens)

Molecular classification
Outer membrane porin, Transmembrane protein, Lipoprotein, Surface-exposed bacterial protein, Surface-exposed bacterial adhesin
01

Overview

The grouping of PorA, factor H binding protein (fHbp), Neisserial adhesin A (NadA), and Neisserial heparin binding antigen (NHBA) as a single target is incorrect. While all are distinct, major outer membrane proteins from Neisseria meningitidis with significant roles in pathogenesis and as vaccine targets, they do not form a single molecular entity. Each possesses unique sequence, structure, and function. The initial query incorrectly combines these separate, well-characterized antigens into one conceptual target. Each component (PorA, fHbp, NadA, and NHBA) is a separate and specific surface antigen on Neisseria meningitidis, critical for virulence and as components in modern meningococcal vaccines, but they are not a single molecular target. Details for each are provided independently in the source material; for accurate data structuring, they should be treated as distinct targets.

02

Mechanism of action

Vaccines containing PorA elicit antibodies, which induce complement-mediated killing of N. meningitidis; Antibody recognition of PorA variable regions triggers bactericidal activity; Elicits protective antibodies that block fHbp binding to factor H, allowing complement-mediated killing; Elicits antibodies that prevent colonization and invasion; Induces protective antibodies.

03

Biological functions

Forms trimeric pores for cation-selective diffusionElicits strong immune (bactericidal antibody) responses in humansContributes to serosubtype variation and immune evasionInvolved in nutrient transportBinds human factor H, downregulating the alternative complement pathway and enabling immune evasionImmune evasionMediates adhesion to human epithelial cellsPromotes bacterial colonization and invasionBinds heparin, likely contributing to immune evasion and endothelial cell interactionHost colonization
04

Disease associations

Infection (critical for Neisseria meningitidis pathogenesis)Immune evasionInfection by Neisseria meningitidis (meningococcal disease)Infection (colonization and invasion during meningococcal disease)Infection (host colonization)
05

Safety considerations

High antigenic variability limits cross-strain vaccine coveragePotential autoimmune cross-reactivity is low but always considered in vaccine antigen selectionSequence variability; coverage of some vaccine fHbp variants may not protect against all strainsPotential antigenic interference with factor H function is generally considered low with current vaccinesLike other meningococcal proteins, antigenic variation can affect vaccine efficacyAntigenic variability
06

Interacting drugs

No small-molecule drugs; targeted by vaccine antigens and bactericidal antibodies

4 more in the full profile.

07

Biomarkers

PorA serosubtype designation is used in epidemiological typing and patient isolate characterizationfHbp sequence variants are used for strain typing and for vaccine coverage predictionsNadA expression is a marker for certain vaccine coverageSequence variants help guide vaccine design and coverage assessments

Beyond the preview

Go deeper on Neisserial heparin binding antigen, Neisserial adhesin A, factor H binding protein, and PorA (Combined Meningococcal Vaccine Antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisserial heparin binding antigen, Neisserial adhesin A, factor H binding protein, and PorA (Combined Meningococcal Vaccine Antigens).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call